This trial is terminated!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Brain Metastasis
and you are
over 20
years old
Phase
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

Vorinostat is a potent and well tolerated HDAC inhibitor. It has been reported to enhance radiosensitivity of cancer cells. We hypothesize that the addition of vorinostat to WBRT may increase therapeutic efficacy for patients with brain metastases.

Provided treatments

  • Drug: Vorinostat
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT01600742. The sponsor of the trial is National Taiwan University Hospital and it is looking for 4 volunteers for the current phase.
Official trial title:
Vorinostat and Concomitant Whole Brain Radiation Therapy in Patients With Brain Metastases: A Randomized, Double-blind, Placebo-controlled, Phase II Study